MCID: OVR114
MIFTS: 66

Ovarian Cancer 1

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Cancer 1

MalaCards integrated aliases for Ovarian Cancer 1:

Name: Ovarian Cancer 1 58 30
Ovarian Carcinoma 12 15 74
Ovarian Cancer, Susceptibility to 58 13
Ovarian Cancer, Susceptibility to, 1 58
Malignant Neoplasm of Ovary 74
Epithelial Ovarian Cancer 74
Ovarian Cancer 58
Ovcas1 58

Classifications:



External Ids:

Disease Ontology 12 DOID:4001
OMIM 58 607893
MeSH 45 C538090
NCIt 51 C4908

Summaries for Ovarian Cancer 1

MalaCards based summary : Ovarian Cancer 1, also known as ovarian carcinoma, is related to hereditary breast ovarian cancer syndrome and hereditary site-specific ovarian cancer syndrome, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer 1 is OVCAS1 (Ovarian Cancer, Epithelial, Susceptibility To), and among its related pathways/superpathways are TGF-Beta Pathway and PI3K-Akt signaling pathway. The drugs Bevacizumab and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include breast, t cells and testes, and related phenotypes are Decreased viability in esophageal squamous lineage and cellular

Description from OMIM: 607893

Related Diseases for Ovarian Cancer 1

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1

Diseases related to Ovarian Cancer 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 602)
# Related Disease Score Top Affiliating Genes
1 hereditary breast ovarian cancer syndrome 34.2 BRCA1 BRCA2 TP53
2 hereditary site-specific ovarian cancer syndrome 33.8 BRCA1 BRCA2
3 ovarian cancer 33.3 AKT1 BRCA1 BRCA2 CDH1 DPH1 ERBB2
4 ovarian clear cell carcinoma 32.5 ARID1A HNF1B KRT7 PIK3CA TP53
5 ovarian disease 32.1 AKT1 BRCA1 BRCA2 TP53 VEGFA
6 granulosa cell tumor of the ovary 31.9 ERBB2 KRT7 TP53
7 pancreatic cancer 31.5 AKT1 BRCA1 BRCA2 CDH1 CEACAM5 ERBB2
8 primary peritoneal carcinoma 30.6 BRCA1 BRCA2 ERBB2 TP53 VEGFA
9 li-fraumeni syndrome 30.5 BRCA1 BRCA2 TP53
10 adenocarcinoma 30.4 AKT1 CDH1 ERBB2 PIK3CA TP53 VEGFA
11 carcinosarcoma 30.4 ERBB2 KRT7 PIK3CA TP53
12 in situ carcinoma 30.3 BRCA1 CDH1 ERBB2 TP53
13 krukenberg carcinoma 30.2 HNF1B KRT7
14 endosalpingiosis 30.2 KRT7 PAX8
15 papillary carcinoma 30.2 CDH1 ERBB2 KRT7 PAX8
16 fallopian tube carcinoma 30.1 BRCA1 BRCA2 ERBB2 TP53 VEGFA
17 endocervical adenocarcinoma 30.1 KRT7 PAX8 TP53
18 clear cell adenocarcinoma 30.1 ARID1A HNF1B KRT7 PAX8
19 transitional cell carcinoma 30.1 CDH1 ERBB2 KRT7 TP53
20 papillary serous adenocarcinoma 30.0 BRCA1 KRT7 TP53
21 cervical adenocarcinoma 30.0 ERBB2 KRT7 TP53
22 wilms tumor 1 30.0 BRCA2 ERBB2 KRT7 PAX8 TP53
23 sporadic breast cancer 30.0 BRCA1 BRCA2 ERBB2 TP53
24 uterine corpus serous adenocarcinoma 29.9 BRCA1 ERBB2 PIK3CA TP53
25 cervical cancer 29.9 AKT1 CDH1 ERBB2 PIK3CA TP53 VEGFA
26 small cell cancer of the lung 29.8 AKT1 CEACAM5 KRT7 PIK3CA TP53
27 intrahepatic cholangiocarcinoma 29.8 ARID1A CDH1 KRT7 TP53
28 ovary epithelial cancer 29.8 AKT1 ARID1A BRCA1 BRCA2 CDH1 CEACAM5
29 renal cell carcinoma, nonpapillary 29.8 CDH1 HNF1B KRT7 PAX8 VEGFA
30 ovarian serous cystadenocarcinoma 29.8 AKT1 ERBB2 PIK3CA TP53
31 breast carcinoma in situ 29.8 BRCA1 BRCA2 ERBB2 TP53 VEGFA
32 breast adenocarcinoma 29.7 AKT1 ERBB2 PIK3CA TP53
33 glioblastoma 29.6 AKT1 BRCA2 ERBB2 PIK3CA TP53 VEGFA
34 serous cystadenocarcinoma 29.6 AKT1 ERBB2 PIK3CA TP53 VEGFA
35 squamous cell carcinoma 29.6 AKT1 CDH1 ERBB2 PIK3CA TP53 VEGFA
36 glioma 29.6 BRCA2 ERBB2 PIK3CA TP53 VEGFA
37 lung cancer 29.6 AKT1 CDH1 CEACAM5 ERBB2 KRT7 PIK3CA
38 papillary adenocarcinoma 29.6 CDH1 CEACAM5 ERBB2 KRT7 TP53
39 ductal carcinoma in situ 29.5 AKT1 BRCA1 BRCA2 CDH1 ERBB2 TP53
40 endometrial cancer 29.5 AKT1 BRCA1 BRCA2 CDH1 ERBB2 KRT7
41 prostate cancer 29.4 AKT1 BRCA1 BRCA2 CDH1 ERBB2 HNF1B
42 squamous cell carcinoma, head and neck 29.4 AKT1 CDH1 ERBB2 PIK3CA TP53 VEGFA
43 colorectal cancer 29.4 AKT1 BRCA1 BRCA2 CDH1 CEACAM5 ERBB2
44 cystadenocarcinoma 29.4 AKT1 CEACAM5 ERBB2 KRT7 PIK3CA TP53
45 gallbladder cancer 29.3 AKT1 CDH1 CEACAM5 ERBB2 PIK3CA TP53
46 lung cancer susceptibility 3 29.1 AKT1 CDH1 CEACAM5 ERBB2 KRT7 PIK3CA
47 hepatocellular carcinoma 29.1 AKT1 CDH1 CEACAM5 KRT7 PIK3CA TP53
48 esophageal cancer 29.1 AKT1 CDH1 CEACAM5 ERBB2 PIK3CA TP53
49 cholangiocarcinoma 29.1 AKT1 CDH1 CEACAM5 ERBB2 KRT7 PIK3CA
50 ovary adenocarcinoma 29.1 ARID1A CEACAM5 ERBB2 ESS2 HNF1B KRT7

Graphical network of the top 20 diseases related to Ovarian Cancer 1:



Diseases related to Ovarian Cancer 1

Symptoms & Phenotypes for Ovarian Cancer 1

Clinical features from OMIM:

607893

UMLS symptoms related to Ovarian Cancer 1:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.32 ARID1A BRCA1 BRCA2 CDH1 ERBB2 HNF1B

MGI Mouse Phenotypes related to Ovarian Cancer 1:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.35 AKT1 ARID1A BRCA1 BRCA2 CDH1 DPH1
2 embryo MP:0005380 10.3 AKT1 ARID1A BRCA1 BRCA2 CDH1 DPH1
3 endocrine/exocrine gland MP:0005379 10.29 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
4 homeostasis/metabolism MP:0005376 10.29 AKT1 ARID1A BRCA1 BRCA2 CDH1 DPH1
5 growth/size/body region MP:0005378 10.27 AKT1 ARID1A BRCA1 BRCA2 CDH1 DPH1
6 mortality/aging MP:0010768 10.22 AKT1 ARID1A BRCA1 BRCA2 CDH1 DPH1
7 integument MP:0010771 10.11 AKT1 BRCA1 BRCA2 CDH1 DPH1 ERBB2
8 neoplasm MP:0002006 10.02 AKT1 ARID1A BRCA1 BRCA2 CDH1 DPH1
9 limbs/digits/tail MP:0005371 9.98 BRCA1 BRCA2 DPH1 ERBB2 PAX8 TP53
10 muscle MP:0005369 9.97 AKT1 ARID1A BRCA1 ERBB2 HNF1B PIK3CA
11 normal MP:0002873 9.81 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
12 no phenotypic analysis MP:0003012 9.8 ARID1A CDH1 ESS2 PAX8 PIK3CA TP53
13 reproductive system MP:0005389 9.7 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
14 skeleton MP:0005390 9.32 AKT1 ARID1A BRCA1 BRCA2 DPH1 ERBB2

Drugs & Therapeutics for Ovarian Cancer 1

Drugs for Ovarian Cancer 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 721)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
2
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
4
Peppermint Approved Phase 4
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
7
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
8
Ferrous fumarate Approved Phase 4,Early Phase 1,Not Applicable 141-01-5
9
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
10
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 114977-28-5 148124
11
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 763113-22-0 23725625
12
Tranexamic Acid Approved Phase 4 1197-18-8 5526
13
Niraparib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1038915-60-4 24958200
14
Aprepitant Approved, Investigational Phase 4,Phase 2,Not Applicable 170729-80-3 151165 6918365
15
Fosaprepitant Approved Phase 4,Phase 2,Not Applicable 172673-20-0 219090
16
Iron Approved, Experimental Phase 4,Phase 2,Not Applicable 7439-89-6, 15438-31-0 23925 27284
17
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
18
Vitamin C Approved, Nutraceutical Phase 4,Phase 1,Phase 2 50-81-7 5785 54670067
19
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
20
Substance P Investigational Phase 4,Phase 2,Not Applicable 33507-63-0 44359816
21 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
33 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
37 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 taxane Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Nutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Retinol palmitate Phase 4,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 2551)
# Name Status NCT ID Phase Drugs
1 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab Unknown status NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
3 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
4 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Active, not recruiting NCT02476968 Phase 4 Olaparib
5 Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
6 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Recruiting NCT03543462 Phase 4
7 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
8 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
9 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
10 NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. Not yet recruiting NCT03752216 Phase 4 Niraparib
11 Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer Not yet recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
12 Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer Recruiting NCT03858166 Phase 4 PEG-rhG-CSF
13 Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations Recruiting NCT03475589 Phase 4 apatinib
14 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
15 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
16 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
17 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
18 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
19 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Recruiting NCT03349463 Phase 4 Fluciclovine F18
20 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
21 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
22 Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
23 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
24 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
25 Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
26 Hydralazine Valproate for Ovarian Cancer Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
27 Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study Unknown status NCT00715286 Phase 3
28 Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
29 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
30 Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
31 Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer Unknown status NCT01802749 Phase 3 Bevacizumab;Paclitaxel;Carboplatin;pegylated liposomal doxorubicin;Gemcitabine
32 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
33 Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer Unknown status NCT01628380 Phase 3
34 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
35 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
36 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
37 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
38 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
39 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
40 Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy Unknown status NCT02097446 Phase 3
41 Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas Unknown status NCT00689715 Phase 2, Phase 3
42 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
43 Violence Against Women and Consequences During Climacteric´s Phase Completed NCT01028118 Phase 3
44 Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer Recruiting NCT01218490 Phase 3
45 A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Completed NCT01847274 Phase 3 Active comparator: Niraparib;placebo
46 Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm Active, not recruiting NCT01461850 Phase 3 Neoadjuvant chemotherapy + Interval Debulking Surgery
47 A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy Terminated NCT01840943 Phase 3 CAELYX;Topotecan HCl
48 CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy Terminated NCT00653952 Phase 3 CAELYX;Paclitaxel HCl
49 A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients Not yet recruiting NCT03863860 Phase 3 Fluzoparib capsules;Placebo capsules
50 Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer Recruiting NCT02681432 Phase 3 HIPEC

Search NIH Clinical Center for Ovarian Cancer 1

Genetic Tests for Ovarian Cancer 1

Genetic tests related to Ovarian Cancer 1:

# Genetic test Affiliating Genes
1 Ovarian Cancer 1 30

Anatomical Context for Ovarian Cancer 1

MalaCards organs/tissues related to Ovarian Cancer 1:

42
Breast, T Cells, Testes, Lung, Ovary, Bone, Lymph Node

Publications for Ovarian Cancer 1

Articles related to Ovarian Cancer 1:

(show top 50) (show all 3641)
# Title Authors Year
1
Effect of Chemotherapeutics and Tocopherols on MCF-7 Breast Adenocarcinoma and KGN Ovarian Carcinoma Cell Lines In Vitro. ( 30766885 )
2019
2
LINK-A Long Non-Coding RNA (lncRNA) Participates in Metastasis of Ovarian Carcinoma and Upregulates Hypoxia-Inducible Factor 1 (HIF1α). ( 30912527 )
2019
3
RGS5 decreases the proliferation of human ovarian carcinoma‑derived primary endothelial cells through the MAPK/ERK signaling pathway in hypoxia. ( 30365142 )
2019
4
Hydropic leiomyoma presenting as a rare condition of pseudo-Meigs syndrome: literature review and a case of a pseudo-Meigs syndrome mimicking ovarian carcinoma with elevated CA125. ( 30635302 )
2019
5
Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma. ( 30467600 )
2019
6
Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors. ( 30501904 )
2019
7
Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil. ( 30606148 )
2019
8
Tunneling Nanotubular Expressways for Ultrafast and Accurate M1 Macrophage Delivery of Anticancer Drugs to Metastatic Ovarian Carcinoma. ( 30608136 )
2019
9
Follicular regulatory T cells infiltrated the ovarian carcinoma and resulted in CD8 T cell dysfunction dependent on IL-10 pathway. ( 30616170 )
2019
10
Galectin-3 regulates chemotherapy sensitivity in epithelial ovarian carcinoma via regulating mitochondrial function. ( 30626779 )
2019
11
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. ( 30633128 )
2019
12
High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature. ( 30636633 )
2019
13
Low grade serous ovarian carcinoma: identifying variations in practice patterns. ( 30640701 )
2019
14
Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study. ( 30640703 )
2019
15
CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy. ( 30642626 )
2019
16
Capn4 regulates migration and invasion of ovarian carcinoma cells via targeting osteopontin-mediated PI3K/AKT signaling pathway. ( 30655802 )
2019
17
Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels. ( 30670303 )
2019
18
Combination of Sonographic Morphology Score and Tumor Markers for Detecting Postoperative Recurrent Pelvic Ovarian Carcinoma: Compared With MRI Assessment. ( 30672869 )
2019
19
SMAD3 inducing the transcription of  STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel. ( 30701575 )
2019
20
Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study). ( 30702598 )
2019
21
Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma. ( 30734108 )
2019
22
The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients. ( 30737418 )
2019
23
Theaflavin-3,3'-Digallate Suppresses Human Ovarian Carcinoma OVCAR-3 Cells by Regulating the Checkpoint Kinase 2 and p27 kip1 Pathways. ( 30769778 )
2019
24
Mortalin is a distinct bio-marker and prognostic factor in serous ovarian carcinoma. ( 30776464 )
2019
25
PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma. ( 30778048 )
2019
26
Novel triazole analogs of apigenin-7-methyl ether exhibit potent antitumor activity against ovarian carcinoma cells via the induction of mitochondrial-mediated apoptosis. ( 30783435 )
2019
27
Effects of human umbilical cord mesenchymal stem cells on co-cultured ovarian carcinoma cells. ( 30790367 )
2019
28
Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma. ( 30795566 )
2019
29
Astaxanthin Combine With Human Serum Albumin To Abrogate Cell Proliferation, Migration, And Drug-Resistant In Human Ovarian Carcinoma SKOV3 Cells. ( 30799797 )
2019
30
Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. ( 30803719 )
2019
31
Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma. ( 30833444 )
2019
32
Novel Bi-Functional 14-mer Peptides with Both Ovarian Carcinoma Cells Targeting and Magnetic Fe₃O₄Nanoparticles Affinity. ( 30841597 )
2019
33
The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1). ( 30853361 )
2019
34
Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium. ( 30862952 )
2019
35
HULC functions as an oncogene in ovarian carcinoma cells by negatively modulating miR-125a-3p. ( 30863948 )
2019
36
Honokiol induces apoptosis and suppresses migration and invasion of ovarian carcinoma cells via AMPK/mTOR signaling pathway. ( 30864681 )
2019
37
Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma. ( 30883751 )
2019
38
Dynamic analysis of proteomic alterations in response to N-linked glycosylation inhibition in a drug-resistant ovarian carcinoma cell line. ( 30884134 )
2019
39
Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma. ( 30887755 )
2019
40
Removal of the entire internal iliac vessel system is a feasible surgical procedure for locally advanced ovarian carcinoma adhered firmly to the pelvic sidewall. ( 30891652 )
2019
41
Enhanced anti-proliferative and pro-apoptotic effects of metformin encapsulated PLGA-PEG nanoparticles on SKOV3 human ovarian carcinoma cells. ( 30892093 )
2019
42
LncRNA AWPPH promotes the proliferation, migration and invasion of ovarian carcinoma cells via activation of the Wnt/β‑catenin signaling pathway. ( 30896797 )
2019
43
Combination of shikonin with paclitaxel overcomes multidrug resistance in human ovarian carcinoma cells in a P-gp-independent manner through enhanced ROS generation. ( 30911326 )
2019
44
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma: Correction. ( 30913186 )
2019
45
lncRNA mortal obligate RNA transcript was downregulated in ovarian carcinoma and inhibits cancer cell proliferation by downregulating miRNA-21. ( 30916806 )
2019
46
Neoadjuvant Chemotherapy Treatment Modifications in Ovarian Carcinoma: The Impact on Surgical Outcome and Progression-free Survival. ( 29889136 )
2019
47
Antrodia salmonea-induced oxidative stress abrogates HER-2 signaling cascade and enhanced apoptosis in ovarian carcinoma cells. ( 30146791 )
2019
48
The role of the long non-coding RNA TDRG1 in epithelial ovarian carcinoma tumorigenesis and progression through miR-93/RhoC pathway. ( 28984384 )
2018
49
P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling. ( 29343281 )
2018
50
TLR4 and NFI_B signaling is critical for taxol resistance in ovarian carcinoma cells. ( 28771725 )
2018

Variations for Ovarian Cancer 1

Expression for Ovarian Cancer 1

Search GEO for disease gene expression data for Ovarian Cancer 1.

Pathways for Ovarian Cancer 1

Pathways related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.5 AKT1 BRCA1 CDH1 ERBB2 HNF1B PIK3CA
2
Show member pathways
12.95 AKT1 BRCA1 ERBB2 PIK3CA TP53 VEGFA
3
Show member pathways
12.75 AKT1 BRCA2 CDH1 ERBB2 PAX8 PIK3CA
4 12.69 AKT1 BRCA2 CDH1 ERBB2 PAX8 PIK3CA
5
Show member pathways
12.68 AKT1 CDH1 ERBB2 PIK3CA TP53
6
Show member pathways
12.53 AKT1 ERBB2 PIK3CA TP53 VEGFA
7 12.47 BRCA1 ERBB2 PIK3CA TP53 VEGFA
8
Show member pathways
12.4 AKT1 ERBB2 PIK3CA TP53
9 12.38 AKT1 CDH1 HNF1B TP53
10
Show member pathways
12.35 AKT1 BRCA1 PIK3CA VEGFA
11
Show member pathways
12.35 AKT1 BRCA1 BRCA2 CDH1 ERBB2 PIK3CA
12
Show member pathways
12.22 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
13 12.21 AKT1 ERBB2 PIK3CA TP53 VEGFA
14
Show member pathways
12.16 AKT1 ERBB2 PIK3CA TP53
15 12.15 AKT1 CDH1 TP53 VEGFA
16 12.1 AKT1 ERBB2 PIK3CA TP53
17 12.05 AKT1 PIK3CA TP53 VEGFA
18
Show member pathways
11.98 AKT1 ERBB2 PIK3CA TP53
19 11.92 AKT1 ERBB2 PIK3CA TP53
20 11.92 AKT1 BRCA1 BRCA2 CDH1 TP53 VEGFA
21
Show member pathways
11.85 AKT1 HNF1B PIK3CA
22 11.85 AKT1 ERBB2 PIK3CA VEGFA
23 11.83 AKT1 PIK3CA TP53
24
Show member pathways
11.82 AKT1 PIK3CA VEGFA
25
Show member pathways
11.76 BRCA1 BRCA2 TP53
26 11.67 AKT1 PAX8 PIK3CA
27 11.66 CDH1 ERBB2 TP53 VEGFA
28
Show member pathways
11.65 AKT1 PIK3CA TP53
29 11.59 AKT1 ERBB2 PIK3CA TP53
30 11.58 AKT1 BRCA1 ERBB2 PIK3CA TP53
31 11.55 AKT1 BRCA1 BRCA2 TP53
32 11.54 AKT1 PIK3CA TP53
33 11.47 AKT1 CDH1 PIK3CA
34 11.47 AKT1 BRCA1 TP53 VEGFA
35 11.46 AKT1 BRCA1 TP53
36 11.45 AKT1 PIK3CA VEGFA
37 11.29 AKT1 CDH1 PIK3CA
38 11.23 AKT1 BRCA1 TP53
39 11.23 AKT1 CDH1 ERBB2 PIK3CA
40 11.09 AKT1 PIK3CA VEGFA
41 10.98 AKT1 CDH1 PIK3CA
42 10.92 AKT1 ARID1A BRCA1 ERBB2 PIK3CA TP53

GO Terms for Ovarian Cancer 1

Cellular components related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.47 AKT1 ARID1A BRCA1 BRCA2 DPH1 ERBB2

Biological processes related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 nervous system development GO:0007399 9.92 AKT1 ARID1A ERBB2 ESS2 VEGFA
2 regulation of apoptotic process GO:0042981 9.85 AKT1 BRCA1 PAX8 TP53
3 cell proliferation GO:0008283 9.85 AKT1 BRCA2 DPH1 ERBB2 TP53
4 negative regulation of apoptotic process GO:0043066 9.77 AKT1 CEACAM5 HNF1B TP53 VEGFA
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.71 AKT1 PIK3CA VEGFA
6 positive regulation of gene expression GO:0010628 9.63 AKT1 BRCA1 ERBB2 HNF1B TP53 VEGFA
7 negative regulation of macroautophagy GO:0016242 9.56 AKT1 PIK3CA
8 anoikis GO:0043276 9.51 AKT1 PIK3CA
9 mesonephric tubule development GO:0072164 9.49 HNF1B PAX8
10 pronephros development GO:0048793 9.48 HNF1B PAX8
11 cellular response to indole-3-methanol GO:0071681 9.43 BRCA1 CDH1
12 phosphatidylinositol 3-kinase signaling GO:0014065 9.43 AKT1 ERBB2 PIK3CA
13 chordate embryonic development GO:0043009 9.4 BRCA1 BRCA2
14 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.32 HNF1B PAX8
15 positive regulation of transcription, DNA-templated GO:0045893 9.23 AKT1 ARID1A BRCA1 BRCA2 CDH1 HNF1B
16 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.13 BRCA1 BRCA2 TP53

Molecular functions related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.26 BRCA1 HNF1B PAX8 TP53
2 identical protein binding GO:0042802 9.23 AKT1 BRCA1 BRCA2 CDH1 CEACAM5 ERBB2
3 GTPase activating protein binding GO:0032794 9.16 AKT1 CDH1

Sources for Ovarian Cancer 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....